Compare iShares Silver Trust (SLV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Zoetis Inc — how do they compare? iShares Silver Trust trades at $58.8, while Zoetis Inc trades at $73.7 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares Silver Trust pays none, and iShares Silver Trust is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| SLV | ZTS | |
|---|---|---|
52-Week High | $105.57 | $156.76 |
52-Week Low | $33.89 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV, tracking physical silver, trades at $59.06, down 0.59% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, though prices eased ahead of CPI data. Financial ratios are not applicable as SLV is a commodity trust.
The outlook for SLV hinges on industrial demand and macroeconomic trends, with upside potential from Fed dovishness but risks from dollar strength and inflation data. Investors gain silver exposure without company fundamentals, making price movements key.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
